CAMP4 Therapeutics (CAMP) Stock: Buy, Sell, or Hold?
CAMP - CAMP4 Therapeutics Corporation Common Stock
$4.01
0.01 (0.25%)
â˛
5d:
+4.16%
30d:
-10.69%
90d:
-8.86%
WAIT
LOW Confidence
Analysis Updated: Oct 5, 2026 12:00 AM ET
Earnings: Nov 05, 2026
29d
Get Alerted When CAMP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CAMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CAMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CAMP is currently trading at $4.01, which is considered fair relative to its 30-day fair value range of $3.86 to $4.29.
Technical Outlook: Technically, CAMP is showing sideways momentum. Immediate support is located at $3.65, while resistance sits at $4.27.
Market Sentiment: CAMP scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.83 (+145.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAMP is showing sideways momentum. Immediate support is located at $3.65, while resistance sits at $4.27.
Market Sentiment: CAMP scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.83 (+145.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.86 -
$4.29
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 145.2% below Wall St target ($9.83)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.86 -
$4.29
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.65
Resistance Level
$4.27
Current Trend
Sideways
Technical data as of
Oct 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.05
Wall Street Target
$9.83
(+145.2%)
Revenue Growth (YoY)
18.8%
Share & Embed Analysis
Last updated: October 05, 2026 7:56 PM ET
Data refreshes hourly during market hours. Next update: 8:56 PM
Data refreshes hourly during market hours. Next update: 8:56 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAMP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals IâĻ |
STRONG BUY
32 analysts |
$571 | 51 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$198 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$110 | 52 HOLD |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$682 | 52 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 65 BUY |
